JNJ-77242113 for Plaque Psoriasis
(ICONIC-TOTAL Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new medication called JNJ-77242113 to see if it can help people with plaque psoriasis in hard-to-treat areas like the scalp, genital area, and palms/soles. The medication works by calming the immune system and slowing down skin cell growth. The goal is to find a more effective treatment for these challenging cases.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if your psoriasis is drug-induced, you may not be eligible to participate.
What safety data exists for JNJ-77242113 in treating plaque psoriasis?
The safety of JAK inhibitors, a group of drugs that includes JNJ-77242113, has been studied in plaque psoriasis. These drugs generally have a safety profile similar to placebo, except for some doses of deucravacitinib. Tofacitinib, another JAK inhibitor, showed a relatively low incidence of side effects.12345
Who Is on the Research Team?
Janssen Research &Development, LLC Clinical trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for people who've had plaque psoriasis, including on the scalp, genitals, or palms and soles of the feet, for at least half a year. They should need systemic treatment or phototherapy and have tried at least one topical therapy without success. Participants must not have non-plaque psoriasis types or skin conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive JNJ-77242113 or placebo for 16 weeks, followed by JNJ-77242113 for up to 156 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-77242113
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University